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Abstract
Background: Bacterial and viral infections are known to promote airway hyperresponsiveness (AHR) in asthmatic patients.
The mechanism behind this reaction is poorly understood, but pattern recognizing Toll-like receptors (TLRs) have recently
been suggested to play a role.
Materials and Methods: To explore the relation between infection-induced airway inflammation and the development of
AHR, poly(I:C) activating TLR3 and LPS triggering TLR4, were chosen to represent viral and bacterial induced interactions,
respectively. Female BALB/c or MyD88-deficient C57BL/6 mice were treated intranasally with either poly(I:C), LPS or PBS
(vehicle for the control group), once a day, during 4 consecutive days.
Results: When methacholine challenge was performed on day 5, BALB/c mice responded with an increase in airway
resistance. The maximal resistance was higher in the poly(I:C) and LPS treated groups than among the controls, indicating
development of AHR in response to repeated TLR activation. The proportion of lymphocytes in broncheoalveolar lavage
fluid (BALF) increased after poly(I:C) treatment whereas LPS enhanced the amount of neutrophils. A similar cellular pattern
was seen in lung tissue. Analysis of 21 inflammatory mediators in BALF revealed that the TLR response was receptor-specific.
MyD88-deficient C57BL/6 mice responded to poly (I:C) with an influx of lymphocytes, whereas LPS caused no inflammation.
Conclusion: In vivo activation of TLR3 and TLR4 in BALB/c mice both caused AHR in conjunction with a local inflammatory
reaction. The AHR appeared to be identical regardless of which TLR that was activated, whereas the inflammation exhibited
a receptor specific profile in terms of both recruited cells and inflammatory mediators. The inflammatory response caused
by LPS appeared to be dependent on MyD88 pathway. Altogether the presented data indicate that the development of
AHR and the induction of local inflammation might be the result of two parallel events, rather than one leading to another.
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Introduction
Respiratory infections, both viral and bacterial, are known to
promote exacerbation and airway hyperresponsiveness (AHR) in
asthmatic patients [1,2,3,4]. The AHR development is often
considered as a result of the inflammatory response, but the
mechanisms behind this are poorly understood. It has become
increasingly clear that activation of the innate immune system
constitutes a critical element in the process [5]. Toll-like receptors
(TLRs) are, as a part of the innate immune system, key elements in
recognizing viral and bacterial components. Detection of microbes
by TLRs evokes an inflammatory response. We, along with several
other research groups, have demonstrated functionally active
TLRs in nearly all cell types implicated in the pathogenesis of
asthma and allergic airway disease, including eosinophils,
neutrophils, mast cells, monocytes, dendritic cells, macrophages,
B-cells, T-cells, epithelial cells and smooth muscle cells
[6,7,8,9,10,11]. Accordingly, several TLRs and TLR ligands have
been associated with the development of asthma [12].
Epithelial and smooth muscle cells are the first to encounter
invading microbes. Cultured human airway smooth muscle cells
express several TLRs, with a pronounced expression of TLR3 and
TLR4 [13]. Polyinosinic polycytidylic acid (poly(I:C)), a synthetic
analogue of viral double-stranded RNA, is a ligand to TLR3 and
lipopolysaccharide (LPS), a major component of the external
membrane of gram-negative bacteria, is a ligand to TLR4.
Poly(I:C) and LPS enhance airway smooth muscle contractions in
vitro [13,14,15]. It is also well known that inflammatory mediators
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32110such as tumor necrosis factor alpha (TNF-a), interleukin-1 beta
(IL-1b) and interferon gamma (IFN-c) have the ability to up-
regulate the TLR expression in airway smooth muscle cells.
Further, if these cell are stimulated with poly I:C or LPS they
increase their expression of several key immunomodulatory
proteins like IL-6, eotaxin (CCL11), IL-8 (CXCL8), interferon
gamma-induced protein 10 kDa (IP-10: CXCL10) and inter-
cellular adhesion molecule 1 (ICAM-1) [16].
The present study was designed to explore the relation between
infection and the development of AHR. To that end, mice were
treated intranasal with either poly(I:C) or LPS followed by
assessment of airway resistance in response to methacholine
(MCh). Cells and cytokine levels in broncheoalveolar lavage fluid
(BALF) were evaluated and MyD88-deficient C57BL/6 mice were
used for further characterisation of pathways involved.
Materials and Methods
Animals
Female BALB/c and MyD88 deficient C57BL/6 mice
(approximately 20 g, 8–12 weeks old) were obtained from Charles
River (Sulzfeld, Germany) and Department of Microbiology,
Tumor and Cell biology (MTC) at the Karolinska Institutet
(Stockholm, Sweden) respectively. The mice were housed in a
conventional animal house with 12-hours dark/light cycles and
kept in plastic cages with adsorbent bedding material. Water and
pelleted food were provided ad libitum. All animal procedures were
approved by the local ethics committee at Karolinska Institutet
(Stockholm norra djurfo ¨rso ¨ksetiska na ¨mnd). Ethical permit
numbers 152/06 and 348/11.
Treatment protocol
On days 1 to 4 the animals were anaesthetized by isoflurane
inhalation and 20 ml of PBS, 0.1 mg/ml LPS from Escherichia coli
0127:B8 (Sigma-Aldrich, St Louis, MO, USA), or 1 mg/ml
lyophilized poly(I:C) (Invivogen, San Diego, CA, USA) were
administered intranasally. Lung mechanics together with collec-
tion of BALF were assessed at day 5, i.e. 24 h after the last
intranasal treatment.
Lung mechanics
Mice were ventilated with the flexiVent
TM animal ventilator
(Scireq, Montreal, Canada). Preparations included anaesthesia
(i.p. pentobarbital sodium, 90 mg?kg
21?bw) and tracheostomy (18-
gauge cannula). Animals were put on a heating pad (body
temperature, 37uC) and connected to the ventilator. After
ventilation was started, bilateral thoracotomy was performed, in
order to equalize pleural pressure to atmospheric and to exclude
chest wall contribution to the mechanics. The ventilation
frequency was 2.5 Hz in a quasi-sinusoidal fashion and by this
mode the pressure waveform was sinusoidal during inflation. The
tidal volume was 12 ml?kg
21 body weight and the positive end-
expiratory pressure (PEEP) was 3 cm H2O. An i.v. catheter was
inserted into the tail vein. Four sigh manoeuvres to three times the
tidal volume were performed in order to stabilize the baseline lung
resistance. After a five minutes resting period, Acetyl-ß-methylcho-
line (Sigma-Aldrich, St Louis, MO, USA) was injected through the
tail vein in increasing doses (0.01, 0.03, 0.1, 0.3, 1 and
3m g ?kg
21?body weight), in order to induce AHR. Lung resistance
(RL) and lung compliance (CL) were measured by assuming a
single-compartment linear model and multiple linear regressions.
Changes in reactivity and sensitivity were assessed using non-linear
regression analysis to calculate the maximum responses (Emax) and
effective dose for half maximal response (ED50).
Broncheoalveolar lavage
BAL was performed directly after lung function measurements.
1 ml PBS containing 0.6 mM ethylendiaminetetraacetic acid
(EDTA) was lavaged three times in the lung. The fluid was
centrifuged at +4uC, 1200 rpm, for 10 minutes and the superna-
tant was stored at 280uC until use. Lysis buffer (150 mM NH4Cl,
10 mM KHCO3, 0.1 mM EDTA, pH 7.2), was used for 2 min, to
lyse the red blood cells, and followed by washing in PBS. Total cell
number was counted and expressed as cells?ml
21 BALF.
Differential cell counts were performed on May-Gru ¨nwald/
Giemsa stained cytospins, counting a minimum of 300 cells, in a
blinded manner.
Measurement of inflammatory mediators
Cytokines in BALF were measured using the Cytokine Mouse
20-Plex Panel together with RANTES Mouse Singleplex Bead Kit
(Invitrogen Corp., Carlsbad, CA, USA) that were run in a
Luminex200 system. The simultaneous immunoassay was carried
out according to instructions of the manufacturer. In brief, specific
antibodies labelled with spectrally encoded beads were applied to
the samples and standards. After incubation, the beads were
washed and mixed with specific biotinylated detector antibodies.
Subsequently, excess of biotinylated antibodies was removed by a
washing step followed by addition of Streptavidin-R-phycoerythrin
(RPE), in order to conjugate and label the detector antibodies. By
monitoring the spectral properties of the beads and the amount of
associated RPE flourescence by the Bio-Plex System (Bio-Rad
Laboratories, Hercules, CA, USA) the concentration of one or
more cytokines could be determined. The cytokines measured
were: fibroblast growth factor (FGF basic, limit of detection (lod)
101 pg/mL), granulocyte macrophage colony-stimulating factor
(GM/CSF, lod 10 pg/mL), IFN-c (lod 1 pg/mL), IL-1a (lod
10 pg/mL), IL-1b (lod 8,7 pg/mL), IL-2 (lod 10 pg/mL), IL-4
(lod 5 pg/mL), IL-5 (lod 6,5 pg/mL), IL-6 (lod 2,7 pg/mL), IL-10
(lod 120 pg/mL), IL-12 (lod 11 pg/mL), IL-13 (lod 20 pg/mL),
IL-17 (lod 5 pg/mL), IP-10 (lod 46 pg/mL), keratinocyte
chemoattractant (KC: CXCL1, lod 11,5 pg/mL), monocyte
chemotactic protein-1 (MCP-1: CCL2, lod4,2 pg/mL), monokine
induced by gamma interferon (MIG: CXCL9, lod 3 pg/mL),
macrophage inflammatory protein-1 a (MIP-1a: CCL3, lod
15,2 pg/mL), TNF-a (lod 4,5 pg/mL), vascular entothelial growth
factor (VEGF, lod 10 pg/mL9) and RANTES (Regulated upon
Activation Normal T-cell Expressed and Secreted: CCL5, lod
60 pg/mL).
Lung histology
Lungs were removed and immersed with 4% buffered
formaldehyde. They were then embedded in paraffin, sectioned
and stained in haematoxylin and eosin. Histological findings such
as peribronchial, parenchymal and perivascular cell infiltration
were semi-quantitatively graded in a blinded manned as 0 to 5
(0=no cell infiltration, 3=moderate, 5=abundant), with a focus
on inflammatory cells.
Statistical analysis
Data were analyzed using Graph Pad Prism, version 5.01,
software (GraphPad Software Inc. San Diego, CA, USA). Results
are presented as mean 6standard error of mean (SEM) and n
equal’s number of subjects. For comparison of data, one-way
analysis of variance (ANOVA) was employed and if significant the
data was further analyzed by Bonferroni post hoc test. ED50 was
analysed as log-values to follow normal distribution. A p-value of
0.05 or less was considered statistically significant.
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Airway hyperresponsiveness
Airway function was assessed in three treatment groups, vehicle
(PBS), poly(I:C) and LPS, before and during intravenous injections
of increasing concentrations of MCh. In BALB/c mice RL values
did not differ between the groups during the initial baseline period.
In the poly I:C group, a decrease in CL compared to vehicle was
found at baseline (p,0.05), in the other groups no baseline
difference in CL was registered. All three groups responded to
MCh with an increase in RL and a decrease in CL. The maximal
resistance (RLmax) in the poly(I:C) and the LPS treated groups,
were higher than in the control group (PBS: RLmax 2.0760.11 cm
H2O?s?ml
21, poly I:C: RLmax 3.3260.12 cm H2O?s?ml
21;
p,0.001 and LPS: RLmax 2.8760.25 cm H2O?s?ml
21;p ,0.01)
(Figure 1A). For the highest MCh dose, the CL was decreased in
both the poly I:C and LPS groups (p,0.001, p#0.05 respectively)
(Figure 1B). No differences in ED50 levels were seen (PBS: ED50
Figure 1. LPS and poly(I:C) induced airway hyperresponsiveness. (A) Changes in lung resistance (RL) and (B) compliance (CL) in response to
methacholine in BALB/c mice treated during 4 days with vehicle (PBS), poly(I:C) or LPS i.n.. Results are expressed as mean 6 SEM. *p,0.05,
***p,0.001 vs. PBS.
doi:10.1371/journal.pone.0032110.g001
Figure 2. Poly(I:C) and LPS induced cell recruitment in BALF. (A, C) Absolute and (B, D) relative cell numbers in BALF in BALB/c mice (A, B)
respectively MyD88deficient C57BL/6 mice (C, D) treated during 4 days with vehicle (PBS), poly(I:C) or LPS i.n.. Results are expressed as mean 6 SEM.
*p,0.05.
doi:10.1371/journal.pone.0032110.g002
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21 body weight, poly(I:C): ED50 0.1860.04
mg?kg
21 body weight, LPS: ED50 0.1960.03 mg?kg
21 body
weight).
The C57BL/6 mice did not develop AHR, regardless of the
treatment given.
Inflammatory response
BALF was collected in order to analyze cells and cytokines. In
BALB/c mice LPS treatment exhibited an increase in total cell
count in comparison with control animals (LPS: 33.064.4610
4
cells, PBS: 4.660.79610
4 cells; p,0.001), whereas this was not
seen for poly(I:C) (poly(I:C): 7.561.0610
4 cells; Figure 2 A).
Examining individual cell types, LPS induced an increased
proportion of neutrophils whereas an increase of lymphocytes
was seen after poly(I:C) treatment (Figure 2 B). A different cell
distribution was found in MyD88 deficient mice, with a significant
increase in the total cell count after poly(I:C) treatment (poly(I:C):
21.067.1610
4 cells, PBS: 5.563.7610
4 cells; p,0.001), whereas
this was not seen following LPS (10.261.8610
4 cells; Figure 2 C).
An increased proportion of lymphocytes was found after poly(I:C)
treatment (Figure 2 D).
In the BALB/c mice LPS also induced an increased infiltration
of inflammatory cells, mainly neutrophils, in the lung tissue, with a
distribution of cells in the peribronchial, perivascular area and also
within the parenchyma. Infiltration was demonstrated as a semi
quantitative score from 0 to 5, where 0=no infiltration (PBS:
0.160.1, LPS: 2.960.6; p#0.001). Poly(I:C) treatment induced an
inflammatory cell influx with predominantly lymphocytes, mainly
in the peribronchial and perivascular areas (poly(I:C): 1.760.3;
p#0.05) (Figure 3). Differentiation of neutrophils and lymphocytes
was made on their morphologic appearance at a high magnifica-
tion (61000).
In order to further dissect potential differences between
poly(I:C) and LPS induced inflammation, 21 cytokines and growth
factors were measured in BALF. The levels of IL-5 IL-12, MCP-1
and KC were increased in the poly I:C treated group (IL-5: PBS:
6.560.0, poly I:C: 17.062.2, p#0.001, IL-12: PBS: 1160.0, poly
I:C: 1360.06197.6, p p#0.001, MCP-1: PBS: 5.360.2, poly I:C:
24.062.8, p#0.001, KC: PBS: 12.460.6, poly I:C: 57.768.5,
p#0.001), whereas MIG and VEGF were increased after LPS
treatment (MIG: PBS: 16.960.7, LPS: 702.1660.5, p#0.001,
VEGF: PBS: 21.165.8, LPS: 70.7615.9, p#0.001) (Figure 4). No
significant differences between the treatment groups where found
for IL-1a, IL-17, MIP-1a, 1L-2, IL-6, IL-13, IP-10, RANTES or
TNF-a. No detectable levels were found for FGF basic, GM/CSF,
IFN-c, IL-1b, IL-4, IL-10 or MIP-1a.
Discussion
The treatment of BALB/c mice with poly(I:C) and LPS during
4 consecutive days resulted in the development of AHR in
conjunction with a local inflammatory reaction. The degree of
AHR was essentially the same irrespectively of which TLR
receptor that was stimulated, whereas the inflammatory response
appeared to be receptor specific. Poly(I:C) caused a limited cell
influx in BALF characterized by an increased proportion of
Figure 3. Poly(I:C) and LPS induced cell recruitment in lung tissue. Haematoxylin and eosin stained cells in BALB/c mice treated i.n. during 4
days with (A) vehicle, (B) poly(I:C) (mainly neutrophils) and (C) LPS (mainly lymphocytes). Magnification is6200. (D) Semi quantitative grading score of
cell infiltration in the lung.
doi:10.1371/journal.pone.0032110.g003
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LPS induced a marked inflammation dominated by neutrophils
together with MIG and VEGF. The neutrophil influx appeared to
be mediated through a MyD88 dependent pathway.
The presented report is the first to compare the effects of
repeated exposure during four consecutive days to LPS and
poly(I:C) on airway resistance. However, acute experiments
demonstrating that LPS [13,14], poly(I:C) [17] and influenza A
(activates TLR3) [18] all can induce AHR have been performed.
We have in a previous study of isolated murine airways
demonstrated that 4 days of treatment with LPS and poly(I:C)
resulted in a marked increase in the contractile response to both
bradykinin and [des-Arg
9]-bradykinin [19]. These findings
support the present AHR data. It is known that both bradykinin
B1 and B2 receptors can contribute to the allergen induced AHR
in rats [20]. Since both TLR3 and TLR 4 are expressed on airway
smooth muscle cells, the presently demonstrated in vivo effects of
poly(I:C) and LPS can be explained by a direct activation of the
airway smooth muscle. [19]. However, the possibility of an
indirect effect has also to be considered. Such a response could be
mediated via the release of inflammatory mediators from the
bronchial epithelium and/or inflammatory airway cells like
macrophages, neutrophils and lymphocytes. All of these cells are
known to express a variety of TLRs including TLR3 and TLR4
[6,8,10].
The present investigation revealed that LPS given to BALC/c
mice caused a severe inflammatory reaction with a marked influx
of neutrophils, whereas the poly(I:C) treatment resulted in a
limited lymphocyte invasion. This is well in line with the literature
demonstrating TLR4 to have ample capacity to facilitate leukocyte
migration [21,22], and poly(I:C) (in the concentration used) to lack
the same effect [17]. It is therefore tempting to conclude that AHR
can be developed without correlation to the recruitment of a
specific set of leukocytes. There are in fact an increasing number of
studies supporting that AHR and airway inflammation may be
dissociated [21,22], patting focuses on local events in the ASM.
Since the same inflammatory mediators could be released from a
variety of cells this assumption does not exclude the possibility of
cytokine/chemokine mediated indirect effect on the airway
smooth muscle [23,24]. We therefore investigated a set of 21
inflammatory mediators in BALF in BALB/c mice treated with
LPS, poly(I:C) and vehicle. Poly(I:C) increased the presence of IL-
5, IL-12, MCP-1 and KC, all known to related to viral stimulation
and lymphocyte activation [25,26]. LPS induced secretion of MIG
and VEGF, involved in neutrophil recruitment and remodelling,
associating LPS to bacterial infections. However, some of our
findings were not so straight forward signifying the complex nature
of in vivo models, where we like in the present experiment, only
have a single time point (at the end of the experiment) for
evaluation a dynamic events known to change over time.
Secondary and tertiary events might explain why, at the end of
the experiment, increased levels of the monocyte chemoattractant
MCP-1 [27] can be found together with a reduced number of
macrophages. This may also explain how KC, a neutrophil
chemoattractant, could be increased after poly(I:C) without
remaining signs of neutrophil recruitment in BALF and vice versa
Figure 4. Poly(I:C) and LPS induced cytokine release in BALF. Levels of (A) IL-5, (B) IL-12, (C) MCP-1, (D) KC, (E) MIG and (F) VEGF in BALB/c
mice treated during 4 days with vehicle (white), poly(I:C) (black) or LPS (gray) i.n. Results are expressed as mean 6 SEM. PBS n=10; poly I:C n=12; LPS
n=13; ***p,0.001.
doi:10.1371/journal.pone.0032110.g004
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TLR3 and TLR4 stimulation. On the contrary, the cytokine
release appeared to be closely related to cells recruited.
TLR4 activates two distinct signalling pathways, one dependent
on adaptors MyD88 and TIRAP (Toll/interleukin-1-receptor
(TIR)-domain-containing adaptor protein). The other pathway,
through TRIF (TIR-domain-containing adapter-inducing inter-
feron-b), is MyD88 independent. The TRIF pathway is also
shared by TLR3. Hence the use of MyD88 deficient mice can
make it possible to distinguish activation caused by TLR4 from
those induced by TLR3. Even though BALB/c mice are known to
be preferred for studies of inflammatory induced AHR, MyD88
deficient mice on BALB/c background are not available. C57BL/
6 mice are recognized to exhibit a low degree of inflammation-
induced AHR but has similar antigen induced cellular levels in
BALF as the BALB/c strain [29,30]. It was therefore expected
that, the repeating of the protocol using the MyD88 deficient
C57BL/6 mice, should cause no AHR development, However,
poly(I:C) caused a raised cell influx in BALF, something that was
not seen after LPS. The low cell count after LPS treatment
indicates that the inflammation is a result of MyD88 dependent
TLR4 signalling and this differs from TLR3, where inflammation
seems to be an effect of MyD88 independent signalling probably
through the TRIF pathway. The absence of AHR in the C57BL/6
mice, to at least poly(I:C), is in accordance with the lower increase
in smooth muscle reactivity to poly(I:C) in C57BL/6 than BALB/c
mice [30], and further argument for that the TLR-induced AHR
is mediated through an effect directly on the smooth muscle.
Acute exacerbations, often seen in association with infection, are
a major cause of morbidity in asthma [25,26]. Far from all asthma
patients benefit from the existing therapeutic alternatives [31]. A
better knowledge of the role of infection in exacerbations might
open the way for new therapeutic interventions. In the present
study poly(I:C) activating TLR3 and LPS triggering TLR4, were
chosen to represent viral and bacterial induced interactions,
respectively. As demonstrated, both types of infections caused
AHR, but the local inflammatory profiles characterized by
inflammatory cell recruitment and cytokine release appeared to
be receptor specific. This challenge the idea that inflammation is
prerequisite for AHR development and suggests that at least part
of the effect might be due to a direct microbial interaction with the
smooth airway musculature [13].
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